<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37223439</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study.</ArticleTitle><Pagination><StartPage>101946</StartPage><MedlinePgn>101946</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101946</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2023.101946</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">'Long COVID' describes persistent symptoms, commonly fatigue, lasting beyond 12 weeks following SARS-CoV-2 infection. Potential causes include reduced mitochondrial function and cellular bioenergetics. AXA1125 has previously increased &#x3b2;-oxidation and improved bioenergetics in preclinical models along with certain clinical conditions, and therefore may reduce fatigue associated with Long COVID. We aimed to assess the efficacy, safety and tolerability of AXA1125 in Long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Patients with fatigue-dominant Long COVID were recruited in this single-centre, double-blind, randomised controlled phase 2a pilot study completed in the UK. Patients were randomly assigned (1:1) using an Interactive Response Technology to receive either AXA1125 or matching placebo in a clinical-based setting. Each dose (33.9&#xa0;g) of AXA1125 or placebo was administered orally in a liquid suspension twice daily for four weeks with a two-week follow-up period. The primary endpoint was the mean change from baseline to day 28 in the phosphocreatine (PCr) recovery rate following moderate exercise, assessed by <sup>31</sup>P-magnetic resonance spectroscopy (MRS). All patients were included in the intention to treat analysis. This trial was registered at ClinicalTrials.gov, NCT05152849.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Between December 15th 2021, and May 23th 2022, 60 participants were screened, and 41 participants were randomised and included in the final analysis. Changes in skeletal muscle phosphocreatine recovery time constant (&#x3c4;<sub>PCr</sub>) and 6-min walk test (6MWT) did not significantly differ between treatment (n&#xa0;=&#xa0;21) and placebo group (n&#xa0;=&#xa0;20). However, treatment with AXA1125 was associated with significantly reduced day 28 Chalder Fatigue Questionnaire [CFQ-11] fatigue score when compared with placebo (least squares mean difference [LSMD]&#xa0;-4.30, 95% confidence interval (95% CI)&#xa0;-7.14,&#xa0;-1.47; <i>P</i>&#xa0;=&#xa0;0.0039). Eleven (52.4%, AXA1125) and four (20.0%, placebo) patients reported treatment-emergent adverse events; none were serious or led to treatment discontinuation.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Although treatment with AXA1125 did not improve the primary endpoint (&#x3c4;<sub>PCr</sub>-measure of mitochondrial respiration), when compared to placebo, there were significant improvements in fatigue-based symptoms among patients living with Long COVID following a four-week treatment period. Further multicentre studies are needed to validate our findings in a larger cohort of patients with fatigue-dominant Long COVID.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Axcella Therapeutics.</AbstractText><CopyrightInformation>&#xa9; 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Finnigan</LastName><ForeName>Lucy E M</ForeName><Initials>LEM</Initials><AffiliationInfo><Affiliation>Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cassar</LastName><ForeName>Mark Philip</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koziel</LastName><ForeName>Margaret James</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Axcella Therapeutics, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradines</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Axcella Therapeutics, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamlum</LastName><ForeName>Hanan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azer</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Axcella Therapeutics, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Axcella Therapeutics, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Hugh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neubauer</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valkovi&#x10d;</LastName><ForeName>Ladislav</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Measurement Science, Slovak Academy of Sciences, Bratislava, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Betty</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05152849</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Mitochondrial dysfunction</Keyword></KeywordList><CoiStatement>MK, JP, KA, DK are employees of Axcella Therapeutics and hold stock options in the company. HM has received consultancy fees from Axcella Therapeutics. BR is a consultant and speaker for, and has received research support from, Axcella Therapeutics. LF, MPC, HL and LV have no relevant conflicts of interest to declare. SN has shares in Perspectum Ltd which is the system and methods for gated mapping of T1 values.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>11</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37223439</ArticleId><ArticleId IdType="pmc">PMC10102537</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2023.101946</ArticleId><ArticleId IdType="pii">S2589-5370(23)00123-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . 2022. WHO Coronavirus (COVID-19) dashboard.https://covid19.who.int/</Citation></Reference><Reference><Citation>Wulf Hanson S., Abbafati C., Aerts J.G., et al. A&#xa0;global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021. medRxiv. 2022</Citation></Reference><Reference><Citation>Healey Q., Sheikh A., Daines L., Vasileiou E. Symptoms and signs of long COVID: a rapid review and meta-analysis. J&#xa0;Glob Health. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9125197</ArticleId><ArticleId IdType="pubmed">35596571</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfarouk K.O., Alhoufie S.T.S., Hifny A., et al. Of mitochondrion and COVID-19. J&#xa0;Enzyme Inhib Med Chem. 2021;36(1):1258&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8205080</ArticleId><ArticleId IdType="pubmed">34107824</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K., Pandey A.K., Livingston A., Venkatesh S. Roles of host mitochondria in the development of COVID-19 pathology: could mitochondria be a potential therapeutic target? Mol Biomed. 2021;2:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8608434</ArticleId><ArticleId IdType="pubmed">34841263</ArticleId></ArticleIdList></Reference><Reference><Citation>Goracy A., Rosik J., Szostak B., Ustianowski L., Ustianowska K., Goracy J. Human cell organelles in SARS-CoV-2 infection: an up-to-date overview. Viruses. 2022;14(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9144443</ArticleId><ArticleId IdType="pubmed">35632833</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze S., Pan D., Moss A.J., et al. Overstimulation of the ergoreflex-A possible mechanism to explain symptoms in long COVID. Front Cardiovasc Med. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9334659</ArticleId><ArticleId IdType="pubmed">35911550</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt H., Ulvestad E., Wyller V.B. Metabolic features of chronic fatigue syndrome revisited. Proc Natl Acad Sci U S A. 2016;113(46)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5135295</ArticleId><ArticleId IdType="pubmed">27810961</ArticleId></ArticleIdList></Reference><Reference><Citation>Daou N., Viader A., Cokol M., et al. A&#xa0;novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models. Sci Rep. 2021;11(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8178416</ArticleId><ArticleId IdType="pubmed">34088912</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison S.A., Baum S.J., Gunn N.T., et al. Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease. Am J Gastroenterol. 2021;116(12):2399&#x2013;2409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8631161</ArticleId><ArticleId IdType="pubmed">34382947</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilcot J., Norton S., Kelly M.E., Moss-Morris R. The Chalder Fatigue Questionnaire is a valid and reliable measure of perceived fatigue severity in multiple sclerosis. Mult Scler. 2016;22(5):677&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">26232100</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwala P., Salzman S.H. Six-minute walk test: clinical role, technique, coding, and reimbursement. Chest. 2020;157(3):603&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7609960</ArticleId><ArticleId IdType="pubmed">31689414</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland A.E., Spruit M.A., Troosters T., et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">25359355</ArticleId></ArticleIdList></Reference><Reference><Citation>Enright P.L., Sherrill D.L. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1384&#x2013;1387.</Citation><ArticleIdList><ArticleId IdType="pubmed">9817683</ArticleId></ArticleIdList></Reference><Reference><Citation>Valkovic L., Chmelik M., Just Kukurova I., et al. Depth-resolved surface coil MRS (DRESS)-localized dynamic (31) P-MRS of the exercising human gastrocnemius muscle at 7 T. NMR Biomed. 2014;27(11):1346&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pubmed">25199902</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerspeer M., Boesch C., Cameron D., et al. 31) P magnetic resonance spectroscopy in skeletal muscle: experts' consensus recommendations. NMR Biomed. 2020;34(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8243949</ArticleId><ArticleId IdType="pubmed">32037688</ArticleId></ArticleIdList></Reference><Reference><Citation>Purvis L.A.B., Clarke W.T., Biasiolli L., Valkovic L., Robson M.D., Rodgers C.T. OXSA: an open-source magnetic resonance spectroscopy analysis toolbox in MATLAB. PLoS One. 2017;12(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5609763</ArticleId><ArticleId IdType="pubmed">28938003</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalder T., Berelowitz G., Pawlikowska T., et al. Development of a fatigue scale. J&#xa0;Psychosom Res. 1993;37(2):147&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">8463991</ArticleId></ArticleIdList></Reference><Reference><Citation>Morriss R.K., Wearden A.J., Mullis R. Exploring the validity of the Chalder Fatigue scale in chronic fatigue syndrome. J&#xa0;Psychosom Res. 1998;45(5):411&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">9835234</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul B.D., Lemle M.D., Komaroff A.L., Snyder S.H. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2021;118(34)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8403932</ArticleId><ArticleId IdType="pubmed">34400495</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavem K., Ghanima W., Olsen M.K., Gilboe H.M., Einvik G. Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: a population-based study. Int J Environ Res Public Health. 2021;18(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7921928</ArticleId><ArticleId IdType="pubmed">33669714</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuzun S., Keles A., Okutan D., Yildiran T., Palamar D. Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19. Eur J Phys Rehabil Med. 2021;57(4):653&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">33393277</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dowds J., O'Brien K., et al. Persistent poor health after COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc. 2021;18(6):997&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456724</ArticleId><ArticleId IdType="pubmed">33413026</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien K., Townsend L., Dowds J., et al. 1-year quality of life and health-outcomes in patients hospitalised with COVID-19: a longitudinal cohort study. Respir Res. 2022;23(1):115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9067558</ArticleId><ArticleId IdType="pubmed">35509060</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;ediv&#xfd; P., Kipfelsberger M.C., Dezortov&#xe1; M., et al. Dynamic 31P MR spectroscopy of plantar flexion: influence of ergometer design, magnetic field strength (3 and 7 T), and RF-coil design. Med Phys. 2015;42(4):1678&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">25832057</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerspeer M., Boesch C., Cameron D., et al. 31P magnetic resonance spectroscopy in skeletal muscle: experts' consensus recommendations. NMR Biomed. 2021;34(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8243949</ArticleId><ArticleId IdType="pubmed">32037688</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell M., Newgard C., Zhang G., Nitzel A., Hamill M., Azer K. LIVRQNac increases fatty acid oxidization in a primary human hepatocyte model of non-alcoholic steatohepatitis. J&#xa0;Hepatol. 2022;77:S718.</Citation></Reference><Reference><Citation>Rossato M.S., Brilli E., Ferri N., Giordano G., Tarantino G. Observational study on the benefit of a nutritional supplement, supporting immune function and energy metabolism, on chronic fatigue associated with the SARS-CoV-2 post-infection progress. Clin Nutr ESPEN. 2021;46:510&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420132</ArticleId><ArticleId IdType="pubmed">34857243</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash A., Kaufman D.L. Oxaloacetate treatment for mental and physical fatigue in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long-COVID fatigue patients: a non-randomized controlled clinical trial. J&#xa0;Transl Med. 2022;20(1):295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9238249</ArticleId><ArticleId IdType="pubmed">35764955</ArticleId></ArticleIdList></Reference><Reference><Citation>Santanasto A.J., Glynn N.W., Jubrias S.A., et al. Skeletal muscle mitochondrial function and fatigability in older adults. J&#xa0;Gerontol A Biol Sci Med Sci. 2015;70(11):1379&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612379</ArticleId><ArticleId IdType="pubmed">25167867</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson C.A., Glynn N.W., Ferrucci L.G., Mackey D.C. Walking energetics, fatigability, and fatigue in older adults: the study of energy and aging pilot. J&#xa0;Gerontol A Biol Sci Med Sci. 2015;70(4):487&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447797</ArticleId><ArticleId IdType="pubmed">25190069</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Wanigatunga A.A., Zampino M., et al. Association of mitochondrial function, substrate utilization, and anaerobic metabolism with age-related perceived fatigability. J&#xa0;Gerontol A Biol Sci Med Sci. 2021;76(3):426&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8355455</ArticleId><ArticleId IdType="pubmed">32803242</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis M., Bromley K., Sutton C.J., McCray G., Myers H.L., Lancaster G.A. Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back! Pilot Feasibility Stud. 2021;7(1):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7856754</ArticleId><ArticleId IdType="pubmed">33536076</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothwell J.C., Julious S.A., Cooper C.L. Adjusting for bias in the mean for primary and secondary outcomes when trials are in sequence. Pharmaceut Stat. 2022;21(2):460&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">34860471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>